|
RU2729401C2
(ru)
|
2012-10-02 |
2020-08-06 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Композиции и способы для иммунотерапии
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
SG11201507026WA
(en)
*
|
2013-02-06 |
2015-10-29 |
Anthrogenesis Corp |
Modified t lymphocytes having improved specificity
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
US11071754B2
(en)
|
2013-03-11 |
2021-07-27 |
Case Western Reserve University |
Method of generating tumor-specific T cells
|
|
US9944898B2
(en)
*
|
2013-03-11 |
2018-04-17 |
Case Western Reserve University |
Method of generating tumor-specific T cells
|
|
EP2970372B1
(en)
|
2013-03-15 |
2020-09-30 |
Celgene Corporation |
Modified t lymphocytes
|
|
AU2014386824B2
(en)
|
2013-03-15 |
2019-05-09 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
US11041021B2
(en)
|
2014-05-23 |
2021-06-22 |
University Of Florida Research Foundation, Incorporated |
Car based immunotherapy
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
ES2688035T3
(es)
*
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
HRP20240357T1
(hr)
*
|
2014-12-24 |
2024-06-07 |
Autolus Limited |
Stanica
|
|
MA41433A
(fr)
*
|
2015-01-26 |
2017-12-05 |
Baylor College Medicine |
Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
|
|
HRP20220890T1
(hr)
*
|
2015-02-06 |
2022-10-14 |
National University Of Singapore |
Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
|
|
US10647778B2
(en)
|
2015-02-09 |
2020-05-12 |
University Of Florida Research Foundation, Incorporated |
Bi-specific chimeric antigen receptor and uses thereof
|
|
US11248058B2
(en)
|
2015-02-19 |
2022-02-15 |
University Of Florida Research Foundation, Inc. |
Chimeric antigen receptors and uses thereof
|
|
WO2016149665A1
(en)
*
|
2015-03-18 |
2016-09-22 |
Baylor College Of Medicine |
Her2/erbb2 chimeric antigen receptor
|
|
WO2016156468A1
(en)
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Polypeptides
|
|
AU2016239949A1
(en)
|
2015-03-31 |
2017-09-07 |
Sorriso Pharmaceuticals, Inc. |
Peptide construct having a protease-cleavable linker
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
TWI833684B
(zh)
*
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體(car)、組合物及其使用方法
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
JP7054924B2
(ja)
|
2015-09-23 |
2022-04-15 |
サイトイミューン セラピューティクス, インコーポレイテッド |
免疫療法のためのflt3指向car細胞
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
GB201518816D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Receptor
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
JP7012645B2
(ja)
*
|
2016-01-11 |
2022-01-28 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
キメラタンパク質および免疫治療の方法
|
|
NZ746700A
(en)
|
2016-04-01 |
2023-04-28 |
Kite Pharma Inc |
Bcma binding molecules and methods of use thereof
|
|
SG10201912519VA
(en)
|
2016-04-01 |
2020-02-27 |
Kite Pharma Inc |
Chimeric receptors and methods of use thereof
|
|
KR102427334B1
(ko)
|
2016-04-01 |
2022-08-03 |
카이트 파마 인코포레이티드 |
키메라 항원 및 t 세포 수용체 및 사용 방법
|
|
CA3019835A1
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
WO2017190096A1
(en)
|
2016-04-29 |
2017-11-02 |
University Of Florida Research Foundation Incorporated |
Chimeric antigen receptors and uses thereof
|
|
US12202856B2
(en)
|
2016-05-19 |
2025-01-21 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
|
|
CN109562126A
(zh)
*
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
CN106635998B
(zh)
*
|
2016-09-14 |
2018-01-09 |
深圳市默赛尔生物医学科技发展有限公司 |
抗体调控的双抗原特异性t细胞及其制备方法和应用
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
BR112019007100A2
(pt)
|
2016-10-07 |
2019-06-25 |
Tcr2 Therapeutics Inc |
composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
|
|
CN109983027A
(zh)
|
2016-10-20 |
2019-07-05 |
细胞基因公司 |
基于cereblon的可异二聚化嵌合抗原受体
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
CN118581046A
(zh)
|
2016-11-22 |
2024-09-03 |
新加坡国立大学 |
用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
|
|
CN110177803A
(zh)
|
2016-11-22 |
2019-08-27 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重新编程的组合物和方法
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
US12590288B2
(en)
|
2017-04-12 |
2026-03-31 |
The Broad Institute, Inc. |
Method of treating an inflammatory disease by administering an agent which binds a surface receptor on a tuft cell that induces an ILC class 2 inflammatory response
|
|
JP2020517259A
(ja)
*
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
CN107267555B
(zh)
*
|
2017-05-27 |
2020-03-20 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
|
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
|
CN118853581A
(zh)
|
2017-06-21 |
2024-10-29 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(CARs)、组合物及其使用方法
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
CA3071282A1
(en)
|
2017-08-10 |
2019-02-14 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
CN109503715B
(zh)
*
|
2017-09-15 |
2023-12-15 |
科济生物医药(上海)有限公司 |
Il-4r的融合蛋白及其应用
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
US12171783B2
(en)
|
2017-11-13 |
2024-12-24 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
|
|
CN109988242A
(zh)
*
|
2018-01-02 |
2019-07-09 |
武汉波睿达生物科技有限公司 |
联合嵌合抗原受体、表达载体、慢病毒及t细胞
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
CN108220238A
(zh)
*
|
2018-01-09 |
2018-06-29 |
郑州大学第附属医院 |
一种减少cd8+t细胞凋亡并增强其功能的培养方法
|
|
WO2019144095A1
(en)
|
2018-01-22 |
2019-07-25 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for car t cells
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Car t細胞療法のための配列決定法
|
|
EP4495246A3
(en)
|
2018-03-01 |
2025-03-26 |
University of Kansas |
Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
JP7584299B2
(ja)
|
2018-05-23 |
2024-11-15 |
ナショナル ユニバーシティ オブ シンガポール |
T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
EP3806894A4
(en)
|
2018-06-12 |
2022-06-08 |
Promab Biotechnologies, Inc. |
PLAP-CAR EFFECTOR CELLS
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
SG11202012653XA
(en)
|
2018-06-19 |
2021-01-28 |
Biontech Us Inc |
Neoantigens and uses thereof
|
|
US20210322473A1
(en)
*
|
2018-07-18 |
2021-10-21 |
The General Hospital Corporation |
Modified t cells and methods of their use
|
|
WO2020033273A1
(en)
*
|
2018-08-04 |
2020-02-13 |
AbCyte Therapeutics Inc. |
Multi-function and multi-targeting car system and methods for use thereof
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
EP3959307A4
(en)
*
|
2019-04-22 |
2023-08-23 |
Nanjing Legend Biotech Co., Ltd. |
Engineered cells and uses thereof
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
CA3144566A1
(en)
|
2019-06-21 |
2020-12-24 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
US12570736B2
(en)
|
2019-06-21 |
2026-03-10 |
Sorriso Pharmaceuticals, Inc. |
Compositions
|
|
JP7692844B2
(ja)
|
2019-06-21 |
2025-06-16 |
ソリッソ ファーマシューティカルズ,インク. |
ポリペプチド
|
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
JP7805928B2
(ja)
|
2019-11-26 |
2026-01-26 |
ノバルティス アーゲー |
Cd19及びcd22キメラ抗原受容体及びその使用
|
|
WO2021106936A1
(ja)
|
2019-11-26 |
2021-06-03 |
日本製鉄株式会社 |
ホットスタンプ成形品及びホットスタンプ用鋼板
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
JP2023522330A
(ja)
|
2020-04-17 |
2023-05-30 |
シティ・オブ・ホープ |
Flt3陽性悪性腫瘍を処置するためのflt3標的化キメラ抗原受容体改変細胞
|
|
CN116249548A
(zh)
|
2020-05-11 |
2023-06-09 |
詹森生物科技公司 |
用于治疗多发性骨髓瘤的方法
|
|
CN116348485A
(zh)
|
2020-07-17 |
2023-06-27 |
英研生物(英国)有限公司 |
提供用于过继性细胞疗法的靶向共刺激的受体
|
|
CN113201063B
(zh)
*
|
2020-07-31 |
2022-04-19 |
北京市神经外科研究所 |
IL7Rα的截短体及其在制备治疗肿瘤的药物中的用途
|
|
TW202306997A
(zh)
|
2021-06-16 |
2023-02-16 |
英商英斯特生物科技有限公司 |
用於在過繼細胞療法中提供標靶共刺激之受體
|
|
EP4370213A4
(en)
|
2021-07-16 |
2025-06-04 |
Instil Bio (Uk) Limited |
Chimeric molecules for targeted costimulation for adoptive cell therapy
|
|
MX2024003887A
(es)
|
2021-10-14 |
2024-07-09 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
|
|
EP4426437A4
(en)
|
2021-11-03 |
2025-09-17 |
Janssen Biotech Inc |
METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
WO2024078485A1
(zh)
*
|
2022-10-11 |
2024-04-18 |
四川大学华西医院 |
一种用于靶向肿瘤微环境的信号感受器和用于靶向治疗肿瘤的细胞
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
CN116178538B
(zh)
*
|
2023-01-05 |
2024-08-02 |
暨南大学 |
靶向热休克蛋白70的纳米抗体及其制备方法与应用
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025072372A1
(en)
*
|
2023-09-26 |
2025-04-03 |
The General Hospital Corporation |
Car-t cells expressing vegf binding proteins
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|